Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
NEW ORLEANS, May 04, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (Nasdaq:MYGN), if they purchased the Company’s securities between August 13, 2014 through March 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Utah.
Get Help
Myriad investors should visit us at https://www.claimsfiler.com/cases/view-myriad-genetics-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Myriad Genetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services, regarding “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to the Company’s hereditary cancer testing dating back to January 1, 2014 (less than four months after the Company launched its myRisk test in September 2013) to the date of the subpoena’s issuance.
On this news, the price of Myriad’s shares plummeted over 12.14%
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
